key: cord-0819947-c64zyt8h
authors: Li, S.; Patel, A.; Heintz, J.; Nance, A.; Rice, A.; Sakellaris, K.; Gemma, S.; Blanton, S. Pedigo; Johnson, M.; Stephan, E.; Kirkby, S.
title: 14: Pregnancy and outcomes in the era of CFTR modulators and COVID-19 pandemic
date: 2021-11-30
journal: Journal of Cystic Fibrosis
DOI: 10.1016/s1569-1993(21)01439-9
sha: 9f2dbd4af1c7b35157658a2e0e2713b188a6d129
doc_id: 819947
cord_uid: c64zyt8h

nan

Background: Acylcarnitines (AC) are critical for mitochondrial fatty acid oxidation as a fuel for cellular energy metabolism, and alterations in plasma AC levels may reflect disrupted metabolism. In non-CF populations, increased plasma AC levels are positively associated with glucose intolerance and increased visceral adipose tissue (VAT)-both of which are elevated in adults with CF. Historical reports in infants with CF suggest low plasma AC compared to healthy controls, although comparisons in adults with CF have not been made. Assessment of AC in adults with CF may provide mechanistic insight into nutritional and/or metabolic perturbations in CF, either as biomarkers for disease progression or as therapeutic targets. We aimed to compare plasma AC concentrations between adults with CF and healthy controls, and to assess plasma AC relationships with body composition and glucose tolerance in adults with CF. Methods: This was a cross-sectional study of n = 27 adults with CF and n = 24 age-matched healthy controls. Fasted blood samples were collected. A panel of 29 plasma AC of varying chain length (short C2-C6, medium C8-C12, long C14-C18) was measured quantitatively using LC-MS. Body composition, including VAT, was measured using dual energy x-ray absorptiometry. Participants without previously diagnosed CF-related diabetes (CFRD) underwent a standard oral glucose tolerance test to determine glucose tolerance status (normal glucose tolerance [NGT, n = 9], impaired glucose tolerance [IGT, n = 6], CFRD [n = 12]). Two sample t tests and ANOVA were used to compare individual AC between groups. Associations of AC with body composition indicators were evaluated using Pearson's correlations. Results: Mean age was 27.8 ± 8.3 yrs; mean BMI was 21.9 ± 3.5 kg/m 2 . Of the 29 AC tested, 3 long-chain AC (C14-OH, C16, C16-OH) were higher in CF compared to controls ( p < 0.05). Among those with CF, 1 short-chain AC (C5) was significantly lower in CFRD compared to NGT and IGT (P < 0.05). BMI was positively associated with C2, C16, C18, and C18:2; VAT was positively associated with C3 and C16; and percent lean mass was inversely associated with C14 (all P < 0.05). Conclusion: Differences in specific plasma AC between individuals with CF and healthy controls, and as a function of glucose tolerance in CF, suggests impaired bioenergetic capacity in adult CF, specifically as CFRD develops. Our data also shows novel associations between specific plasma acylcarnitines and body composition in CF. These results point to altered metabolism of fatty acids as a potentially contributing factor to, or biomarker of, metabolic disease in CF. Acknowledgements: Funding: Cystic Fibrosis Foundation and National Institutes of Health. Background: In line with existing literature, which supports increased fertility for women with CF on CFTR modulators, our center experienced a large increase in pregnancies following the initiation of elexacaftor/ tezacaftor/ivacaftor. In response, we developed a standard approach to prenatal care. Methods: We assembled a multidisciplinary team of physicians, dietitians, pharmacists, nurses, mental health coordinators, and genetic counselors that met every other week. At the identification of pregnancy, or desire for conception, a complete assessment was done to identify risk factors for pregnancy, including advanced lung disease, malnutrition, CFRD, impaired glucose tolerance (IGT), mental health disorders, and high-risk medication use. Women were immediately referred to maternal fetal medicine, and those with baseline CFRD or IGT were referred to endocrinology. We aimed to see women ≥2 times per trimester. Results: Pregnancy outcomes: Between March 2020 and March 2021, 21 women at our center became pregnant (compared with 18 from 1996 to 2011). This represents a pregnancy rate of 16% in women of childbearing age between 15-44 years at our center, compared with 2.5% in 2014 nationally [1] . Of these, the woman was taking elexacaftor/tezacaftor/ ivacaftor in 90% (19) of cases at the time of conception, and 86% (18) remained on it throughout pregnancy. Of the 4 (19%) with advanced lung disease (ALD) with FEV1 <40%, 1 woman was admitted twice (for CF exacerbation and COVID-19), 1 admitted for dyspnea due to gravid twin uterus (not given antibiotics), 1 received bamlanivimab for COVID-19 at an ER, and 1 did not require hospitalization or ER visits. Of 10 (48%) patients who had baseline CFRD, 7 were placed on a continuous glucose monitor, 1 preferred to continue to check via finger stick, and 2 had early firsttrimester abortions. Three (14%) had baseline IGT, all of whom developed gestational diabetes during pregnancy. One was started on insulin therapy, while others chose dietary control. Thirteen (62%) of 21 pregnant women had a baseline mood disorder. 8 of 13 (62%) had worsening mood symptoms during pregnancy but declined linkage to mental health resources. Fetal outcomes: There have been 8 deliveries of live births to date, 3 (38%) of which were preterm and 5 (62%) were term, 4 (50%) were delivered vaginally and 4 (50%) by cesarean, and 3 (38%) had ALD. For mothers with baseline CFRD, 4 had successful deliveries of 5 total infants, only 1 of whom was large for gestational age and 1 with intrauterine growth restriction due to twin-twin gestation. Only 1 patient with gestational diabetes has delivered thus far. She decided to use dietary control and delivered early at 34 weeks. Conclusion: As a single center, we have observed a steep rise in the rate of pregnancies since the approval of elexacaftor/tezacaftor/ivacaftor. Through a multidisciplinary approach, we have had fairly uncomplicated pregnancy and delivery courses despite the COVID-19 pandemic. Follow-up and access to specialty care remains a challenge for many women. Our approach highlights an opportunity for developing a protocolized approach for pregnancy in CF that focuses on comprehensive, multidisciplinary care with regular reviews and facilitated communication between specialists. Association of estrogen supplementation with bone turnover markers in women with cystic fibrosis M. Wu 1 , W. Hunt 2 , V. Tangpricha 3 . 1 Emory University School of Medicine, Atlanta, USA; 2 Pulmonology and Critical Care, Emory University School of Medicine, Atlanta, USA; 3 Division of Endocrinology, Metabolism and Lipids, Emory University School of Medicine, Atlanta, USA Background: Low bone mineral density (BMD) affects 25% of adults with CF. Many factors modify CF-related bone disease (CFBD) including estrogen, which is necessary for females to attain and maintain their peak bone mass [1] . Other factors include vitamin D deficiency and CFTR dysfunction. CFTR modulator therapy is promising, but studies have not consistently found benefit for CFBD [3] . Previous observational studies of estrogen supplementation in women with CF have raised concerns that oral ethinyl estradiol in oral contraceptives (OC) is inadequate to promote bone accrual in premenopausal women with CF, and that the age at which the patient begins estrogen supplementation affects bone accrual [4, 5] . In non-CF populations, similar doses of ethinyl estradiol < 30 mcg/day in OC are associated with decreased bone accrual, but higher doses of ethinyl estradiol in OC and other formulations of estrogen (estradiol and conjugated estrogens) have improved BMD. The objective of this analysis was to investigate the association of estrogen supplementation use and 2 markers of bone turnover: C-terminal telopeptides of type I collagen (CTX-1, marker of bone resorption) and propeptide of type I procollagen (PINP, marker of bone formation). Methods: Women with CF ages 16-50 years were interviewed regarding estrogen use and provided samples for an IRB-approved cross-sectional study investigating associations of bone health and inflammation with estrogen supplement use. CTX-1 and P1NP were measured in plasma by chemiluminescent immunoassay (Immunodiagnostic Systems, Gaithersburg, MD). Differences in CTX1 and P1NP were compared between the estrogen supplemented and non-supplemented groups with Wilcoxon rank sum test. The correlation of CTX1 and P1NP was examined with Spearman rank. Results: Of the 23 subjects analyzed in this cross-sectional study, the 8 exposed and 15 unexposed women had similar baseline characteristics.

Their median age was 26.3 years, median FEV1 75.5% pred, 91% were taking vitamin D supplementation, median 25(OH)D was 34 ng/mL, and 43% reported a previous fracture. The exposed women were taking 20-30 mcg ethinyl estradiol with progesterone OC. Their median age at first estrogen use was 20 years; the duration of use was 0.5-18 years. None had used estradiol or conjugated estrogens. CTX1 and P1NP were similar in estrogen supplemented and non-supplemented women (Figure 1 ). CTX1 and P1NP had a correlation coefficient of 0.6 (P 0.003). Conclusion: Estrogen supplementation did not suppress CTX1 and P1NP in women with CF. In adults, lower markers of bone turnover are associated with decreased fracture risk. Limitations of this study include small sample, variability in estrogen exposure and sampling during routine clinic visit. CTX-1 is affected by circadian rhythm and prandial state; ideal collection is after an overnight fast. CTX-1 and P1NP did correlate suggesting that bone resorption is coupled to bone formation which is physiologic. In this crosssectional study of women with CF, estrogen supplementation was not associated with decreased markers of bone turnover, but prospective studies are needed to understand the role of estrogen supplementation in preventing and treating CFBD.

Pregnancy among cystic fibrosis women in the era of CFTR modulators

Continuous glucose monitors in CFRD screening: What can they do?

Acknowledgements: This work was supported by NIH Awards TL1TR002382 and UL1TR002378 and CFF Award WU20D0. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Background: Cystic fibrosis-related diabetes (CFRD) impacts 20% of adolescents and 40-50% of adults with CF. Current guidelines recommend annual diabetes screening with a 2-hour oral glucose tolerance test (OGTT) beginning at age 10. Adherence to screening recommendations is low, with